|
TRIAL NAME |
DATE OPENED |
| BREAST |
A phase III, randomized clinical trial of trial of standard adjuvant endocrine therapy +/- chemotherapy in patients with 1-3 positive nodes, hormone receptor-positive and HER2-negative breast cancer with recurrence score (RS) of 25 or less.
BCCA CODE: BRMAC15 |
December 2011 |
| |
A phase II, randomized, double-blind, placebo controlled, multicentre study to assess the efficacy and safety of AZD8931 in combination with Anastrozole, compared to Anastrozole alone, in post-menopausal women with hormone receptor-positive, endocrine therapy-naive, locally advanced or metastatic breast cancer.
BCCA CODE: BRTMINT |
November 2011 |
| |
A phase II prospective trial correlating progression free survival with CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen.
BCCA CODE: BRECOG3108 |
September 2011 |
| |
A randomized, multicentre, phase III open-label study of the efficacy and safety of Trastuzumab-MCC-DM1 vs. Capecitabine + Lapatinib in patients with HER2 positive locally advanced or metastatic breast cancer who have received prior Trastuzumab-based therapy
BCCA CODE: BRTTLC |
January 2011 |
| |
A phase II study of RO4929097 in advanced metastatic or recurrent triple negative invasive breast cancer.
BCCA CODE: BRPHL076 |
January 2011 |
| |
A phase II clinical trial to evaluate 18F-Fluorestradiol positron emission tomography / computerized tomography (PET/CT) guided fulvestrant therapy for patients with rosarian or metastatic breast cancer
BCCA CODE: BRTFULCT |
November 2010
On Hold |
| |
A phase I/II study of Foretinib in combination with Lapatinib in patients with human epidermal growth factor receptor 2 (HER2) over-expressing metastatic breast cancer.
BCCA CODE: P1IND198 |
October 2010
On Hold
|
| |
A phase II study of Foretinib in patients with estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2) negative, recurrent/metastatic breast cancer.
BCCA CODE: BRIND197 |
October 2010 |
| |
A Phase III randomized trial of metformin versus placebo on recurrence and survival in early stage breast cancer.
BCCA CODE: BRMA32 |
August 2010
|
| |
Phase I/II Open-Label, Randomized Study of the Safety, Efficacy, and Pharmacokinetics of Letrozole Plus PD0332991 (oral CDK 4/6 inhibitor) and Letrozole single Agent for the First Line Treatment of ER Positive, HER2 Negative Advanced Breast Cancer in Postmenopausal Women.
BCCA CODE: BRTLETPD |
July 2010
|
| |
A randomized, multicentre, multinational phase ll study to evaluate pertuzumab in combination with trastuzumab given with or concomitantly or sequentially with standard anthracycline based chemotherapy or concomitantly with a non-anthracycline based chemotherapy regimen, as neoadjuvant therapy for patients with locally advanced, inflammatory or early stage HER2-positive breast cancer.
BCCA CODE: BRT22280 |
February 2010 |
|
Back to Top
|
| CENTRAL NERVOUS SYSTEM (CNS) |
A phase ll study of PX-866 in patients with Glioblastoma multiforme at time of first relapse or progression
BCCA CODE:CNIND204 |
June 2011 |
| |
A randomized, double-blind, placebo-controlled, multicentere phase lll trial of Bevacizumab, Temozolomide and Radiotherapy, followed by Bevacizumzab and Temozolomide versus placebo, Temozolomide and Radiotherapy followed by Placebo and Tomozolomide in patients with newly diagnosed Glioblastoma.
BCCA CODE:CNTB021990 |
March 2010 |
|
Back to Top
|
| GASTROINTESTINAL (GI) |
A randomized phase II study of Everolimus alone versus Everolimus plus Bevacizumab in patients with locally advanced or metastatic pancreatic neuroendocrine tumors
BCCA CODE: GINEC2 |
October 2011 |
| |
A phase 3, multicentre, randomized, double-blind, placebo controlled, trial of AMG 479 or placebo
BCCA CODE: GIT479GEM |
October 2011 |
| |
A phase III trial of 6 versus 12 treatments of adjuvant FOLFOX plus Celecoxib or placebo for patients with resected stage lll colon cancer.
BCCA CODE: GICRC6 |
September 2011 |
| |
A phase II study of MK-2206 (NSC-749607) as second line therapy for advanced gastric and gastroesophageal junction cancer.
BCCA CODE: GIS1005 |
June 2011 |
| |
A phase lll randomized study of Sorafenib (IND 69896, NSC 724772) plus Doxorubicin versus Sorfenib in patients with advanced hepatocellular carcinoma (HCC)
BCCA CODE: GIHEC.1 |
May 2011 |
| |
An open-label, multicentre, randomized phase 2 study evaluating the safety and efficacy of 5-FU/FA and Oxaliplatin (modified FOLFOX-6) in combination with IMC-1121B or INC-18F1 or with out investigational therapy as second-line therapy in patients with metastatic colorectal cancer following disease progression on first-line irinotecan-based therapy.
BCCA CODE: GITCPO801 |
October 2010 |
| |
A phase lll trial of Irinotecan/5-FU/Leucovorin or oxaloplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225) or with the combination of Bevacizumab and Cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum
BCCA CODE: GICRC5 |
September 2010 |
| |
A randomized phase 3 study of capecitabine or 5-fluorouracil-based regimen with or without oxaliplatin as 2nd line treatment of advanced or metastatic pancreatic cancer in patients who have received gemcitabine-based chemotherapy.
BCCA CODE: GITPANCREO |
September 2010 |
| |
A multicentre, double-blind, 3-arm, phase 1b/2 study in subjects with unresectable locally advanced or metastatic gastric or esophogastric junction adenocarcinoma to evaluate the safety and efficacy of first-line treatment with epirubicin, cisplatin, and capecitabine (ECX) plus AMG 102.
BCCA CODE: GITECX102 |
March 2010 |
| |
An exploratory trial of biomarkers for Panitumumab response among previously treated patients with metastatic colorectal cancer.
BCCA CODE: GITPANKRAS |
October 2009
ON HOLD |
| |
A phase lll study of the impact of a physical activity program on disease-free survival in patients with high risk stage ll or stage lll colon cancer: a randomized controlled trial (challenge)
BCCA CODE: GICO21 |
July 2009 |
| |
A multinational, randomized, double-blind study comparing efficacy of Aflibercept once every 2 weeks versus placebo in patients treated with Gemcitabine for metastatic pancreatic cancer
BCCA CODE: GITVANILLA |
August 2008 |
| |
A randomized, open-label phase lll study to assess efficacy and safety of bevacizumab in combination with capecitabine as first line treatment for elderly patients with metastatic colorectal cancer.
BCCA CODE: GITAVEX |
March 2008
On Hold |
|
Back to top
|
| GENTOURINARY (GU) - Bladder |
An open-label, multicentre, randomized phase 2 study evaluating the safety and efficacy of docetaxel in combination with ramucirumab (IMC-1121B) drug product or IMC-18F1 or without investigational therapy as second-line therapy in patients with locally advanced or metastatic transitional cell carcinoma of the bladder, urethra, ureter or renal pelvis following disease progression on first-line platinum-based therapy.
BCCA CODE: GUTCP0902 |
March 2011 |
| |
A phase II, single arm, single agent, multicentre, adaptive 2-stage study to evaluate the efficacy and pharmacokinetics of AZD4877 administered weekly in patients with recurrent advanced urothelial cancer.
BCCA CODE: GUTAZD48 |
October 2008 |
| |
|
|
| GENTOURINARY (GU) - Kidney |
An open-label, randomized, multicentre phase II study to compare the safety and efficacy of TK1258 and Sorafenib in patients with metastatic renal cell carcinoma after failure on anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies
BCCA CODE: GUTTK1258 |
August 2011 |
| |
A randomized phase ll study of Afinitor (Everolimus) Versus Sutent (Sunitinib) in patients with metastatic non-clear cell renal cell carcinoma
BCCA CODE: GUTASPEN |
July 2011 |
| |
An open-label, multicentre phase ll study to compare the efficacy and safety of RAD001 as first-line RAD001 in the treatment of patients with metastatic renal cell carcinoma
BCCA CODE: GUTRADSUNI |
November 2010 |
| |
A phase 2 study of RO4929097 (IND 109291) in patients with advanced renal cell carcinoma (RCC, NOS 10038415) that has progressed after VEGF/VEGFR directed therapy
BCCA CODE:GUPHL077 |
September 2010 |
| |
|
|
| GENTOURINARY (GU) - Prostate |
A phase 2 randomized study of Cediranib (AZD2171) alone compared with the combination of Cediranib (AZD2171) plus BMS-354825 (Dasatinib, Sprycel) in Docetaxel resistant, castration resistant prostate cancer
BCCA CODE:GUPJC002 |
November 2011 |
| |
A phase ll study of PX-866 in patients with recurrent or metastatic castration resistant prostate cancer.
BCCA CODE:GUIND205 |
November 2011 |
| |
An open-label study to determine the short-term safety of continuous dosing of Abiraterone Acetate and Prednisone in modified fasting and fed states to subjects with metastatic castration-resistnant prostate cancer.
BCCA CODE: GUTPCR2008 |
September 2011 |
| |
An open-label study of Abiraterone Acetate in subjects with metastatic castration resistant prostate cancer who have progressed after Taxane-based chemotherapy.
BCCA CODE: GUTABEAP |
June 2011 |
| |
A randomized phase 3 study comparing standard first-line docetaxel/prednisone to docetaxel/prednisone in combination with custirsen (OGX-011-11) in men with metastatic castrate resistant prostate cancer.
BCCA CODE: GUTCUSDOC |
December 2010 |
| |
A randomized phase II study of OGX-427 ( a second-generation antisense oligonuclueotide to Heat shock protein-27) in patients with castration resistant prostate cancer who have not previously received chemotherapy for metastatic disease)
BCCA CODE: GUTPRO1 |
December 2010 |
| Back to top |
| GYNE |
A phase 3, randomized, double-blind trial of weekly Paclitaxel plus AMG 386 or placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancers.
BCCA CODE: GOTAMG386 |
August 2011 |
| |
A phase ll, single-arm study of orally administered BKM 120 as second-line therapy in patients with advanced endometrial carcinoma.
BCCA CODE: GOTC2201 |
April 2011 |
| |
A phase ll/lll study of intraperitoneal (IP) plus intravenous (IV) chemotherapy versus IV carboplatin plus paclitaxel in patients with epithelial ovarian cancer optimally debulked at surgery following neoadjuvant intravenous chemotherapy.
BCCA CODE: GOOV21 |
June 2010 |
| |
A phase lll open label, randomized, 2 arm study of Ixabepilone administered every 21 days versus Paclitaxel or doxorubicin administered every 21 days in women with advanced endometrial cancer who have previously been treated with chemotherapy.
BCCA CODE: GOTIXPAD |
April 2010 |
| |
| HEAD & NECK |
|
|
| |
A randomized, double-blind, placebo-controlled, phase lll study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients with state lll, lVa or lVb loco-regionally advanced head and neck squamous cell carcinoma.
BCCA CODE: HNTAFA |
January 2012 |
| Back to top |
| LUNG |
A phase l/ll study of GSK 1363089 in patients with previously treated non-small cell lung receiving standard Erlotinib Therapy.
BCCA CODE: LUIND196 |
May 2010 |
| |
A double blind placebo controlled randomized trial of PF-804 in patients with incurable stage lllB/lV Non-small cell lung cancer after failure of standard therapy for advanced or metastatic disease.
BCCA CODE: LUBR26 |
April 2010 |
| Back to top |
| LYMPHOMA |
An open-label, multicentre, phase l trial of the safety and pharmacokinetics of escalating doses of DCDS4501 in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
BCCA CODE: LYTDCS4968 |
July 2011 |
| |
An open-label, multi-centre, randomized, phase III study to investigate the efficacy and safety of Bendamustine compared with Bendamustine + RO5072759(GA101) in patients with Rituximab-Refractory, indolent Non-Hodgkin's Lymphoma
BCCA CODE: LYBDGA101 |
October 2010 |
| |
A randomized, double-blind, pacebo-controlled study to assess the efficacy and safety of CNTO 328 (Anti-IL-6 Monoclonol Antibody) plus Best Supportive Care compared with Best Supportive Care in subjects with multicentric castleman's disease.
BCCA CODE: LYTCNT0328 |
September 2010 |
| |
A phase II trial tailoring first-line therapy for advanced stage diffuse large B-cell Non-Hodgkin's Lymphoma based on mid-treatment positron Emission Tomography (PET) scan results
BCCA CODE: LYPET |
August 2006 |
| Back to top |
| PHASE 1 |
A phase 1, non-randomized open-label study to evaluate the effect of BAY73-4506 (regorafenib) on probe substrates of CYP 2C9 (warfarin), 2C19 (Omperazole) and 3A4 (midazolam) in a cocktail approach (Group A) and on a probe substrate of CYP 2C8 (rosiglitazone, Group B) in patients with advanced solid tumors.
BCCA CODE: P1TB12434 |
October 2011 |
| |
A phase 1b study of LCL161 in combination with weekly paclitaxel in adult patients with advanced solid tumors.
BCCA CODE: P1TLCL161 |
August 2011 |
| |
A phase 1 open-label, multicenter dose-escalation study of BB1608 administered with Paclitaxel to determine the safety, tolerability and recommended phase 2 dose of BB1608 in adult patients with advanced malignancies.
BCCA CODE: P1TBB1608 |
April 2011 |
| |
A phase I/II trial of BMS-754807 in combination with Cetuzimab (erbitux®) as a therapy for subjects with advanced or metastatic solid tumors.
BCCA CODE: P1T754CET |
August 2010 |
| |
Open-label dose-escalation trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of daily oral MGCD265 administered without interruption to subjects with advanced Malignancies.
BCCA CODE: P1TMG265 |
June 2008 |
| |
Phase I, Open-label, multiple dose study to assess the safety, tolerability and pharmacokinetics of ARRAY-380 given on a daily oral regimen in subjects with advanced cancer
BCCA CODE:P1TAR380 |
May 2008 |
| |
| SARCOMA |
|
|
| Back to top |
| SKIN - MELANOMA |
An open-label, multicentre expanded access study of RO5185426 in patients with metastatic melanoma.
BCCA CODE: SMT25515 |
July 2011 |
| |
A multicenter treatment protocol for expanded access use of Ipilimumab (BMS-734016) monotherapy in subjects with unresectable stage lll or stage IV melanoma.
BCCA CODE: SMITIPI |
March 2011 |
| |
A randomized phase II study of Interleukin-21 (rIL-21) versus Dacarbazine (DTC) in patients with metastatic or recurrent melanoma
BCCA CODE: SMIND202 |
October 2010 |
| Back to top |
| SYMPTOM MANAGEMENT |
A phase I study to determine the dose of methadone as first line agent in the treatment of chronic neuropathic cancer pain.
BCCA CODE SCSC22 |
May 2010 |